<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04978181</url>
  </required_header>
  <id_info>
    <org_study_id>recanalization deterioration</org_study_id>
    <nct_id>NCT04978181</nct_id>
  </id_info>
  <brief_title>The Prevalence and Associated Factors of Early Deterioration After Successful Recanalization in Acute Ischemic Stroke</brief_title>
  <official_title>The Prevalence and Associated Factors of Early Neurological Deterioration After Successful Recanalization Treatment in Patients With Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      stroke is a leading cause of morbidity and mortality worldwide. More than half (54.5%) of the&#xD;
      56.9 million deaths worldwide in 2106 were due to the top 10 causes.&#xD;
&#xD;
      Ischemic heart disease and stroke are the world's biggest killers, accounting for a combined&#xD;
      15.2 million deaths in 2106. These diseases have remained the leading causes of death&#xD;
      globally in the last 15 years.&#xD;
&#xD;
      Recent clinical trials have shown that endo-vascular thrombectomy is an effective and safe&#xD;
      recanalization modality for acute ischemic stroke patients .&#xD;
&#xD;
      Meta-analysis results show that endovascular treatment is associated with a high ratio of&#xD;
      successful recanalization rate and a low rate of symptomatic hemorrhage .&#xD;
&#xD;
      Approximately 2.2-37.5% of patients with acute ischemic stroke might encounter early&#xD;
      neurological deterioration (END).&#xD;
&#xD;
      Definition of END: An increase in NIHSS ≥4 or an increase in Ia of NIHSS ≥1 within 72 h after&#xD;
      recanalization treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of early neurological deterioration after successful recanalization treatment in patients with acute ischemic stroke</measure>
    <time_frame>1 year</time_frame>
    <description>Prevalence of early neurological deterioration after successful recanalization treatment in patients with acute ischemic stroke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>factors of deterioration</measure>
    <time_frame>1 year</time_frame>
    <description>factors of deterioration</description>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute Stroke</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alteplase Injection</intervention_name>
    <description>thrombolytic therapy for acute ischemic stroke in time window</description>
    <other_name>thrombolysis</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients admittedto Assiut University Hospitals within time window for thrombolysis or&#xD;
        thrombectomy within one year are included&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ischemic stroke of both sex.&#xD;
&#xD;
          2. More than 08 years.&#xD;
&#xD;
          3. Accepting all study requirements.&#xD;
&#xD;
          4. within time window for thrombolysis or thrombectomy&#xD;
&#xD;
          5. fulfilling criteria for thrombolysis or thrombectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        (A)Absolute Contraindications :&#xD;
&#xD;
          1. Intracerebral hemorrhage history or presence on imaging&#xD;
&#xD;
          2. Time of onset more than 465 hours&#xD;
&#xD;
          3. Blood pressure greater than 085/000 mm Hg&#xD;
&#xD;
          4. Recent severe head trauma or neurosurgical intervention&#xD;
&#xD;
          5. Coagulopathy (INR &gt;067, thrombocytopenia, recent use of heparin or direct oral&#xD;
             anticoagulants)&#xD;
&#xD;
          6. Endocarditis (infective)&#xD;
&#xD;
          7. Aortic dissection (B)Potential Contraindications :&#xD;
&#xD;
        1.Seizure at onset 2.Noncompressible arterial puncture 3.Recent surgery 4.Gastrointestinal&#xD;
        or genitourinary bleeding 5.Multiple cortical microbleeds (&gt;00) 6. Large intracranial&#xD;
        aneurysms or arteriovenous malformations 7.Recent transmural myocardial infarction 8. Small&#xD;
        NIHSS with nondisabling stroke symptoms&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 16, 2021</study_first_submitted>
  <study_first_submitted_qc>July 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2021</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Osama Ibrahim Aboelfath Ibrahim</investigator_full_name>
    <investigator_title>osama ibrahim abo-elfath</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

